Purchase this article with an account.
Afsheen A. Khwaja, Owhofasa Agbedia, Yasir J. Sepah, Abeer Akhtar, Mohamed Ibrahim, Raafay Sophie, Peter A. Campochiaro, Diana V. Do, Quan D. Nguyen, READ-3 Study Group; Comparison of Treatment of Fellow Eyes treated with Ranibizumab with Study Eye of Patients Enrolled in the READ-3 Study. Invest. Ophthalmol. Vis. Sci. 2012;53(14):4668.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the outcomes of Fellow Eye (FE) treated with ranibizumab (RBZ) with that of the Study Eye (SE) of patients enrolled in READ-3 Study.
The READ-3 study evaluates two different doses (0.5mg and 2.0mg) of RBZ for DME. SE was randomized to one of two doses. In addition, FEs, if eligible, were also treated with RBZ.44 eligible patients consented for FE treatment and were treated with dose of RBZ opposite that to which the SE was randomized. The FEs were treated with three consecutive doses of RBZ at monthly intervals and then continued to receive the same dose of RBZ based on retreatment criteria(>250um). The maximum number of consecutive injections that the FE could receive was 3. Patients who did not receive at least 3 consecutive injections were excluded from the analysis.
Both low and high doses of RBZ have demonstrated similar efficacy in reducing retinal thickness and improving visual acuity in eyes with DME. Such findings are demonstrated by both intra and inter-patient comparisons. In any individual patient, 0.5 mg or 2.0 mg doses of RBZ show comparable outcomes in acuity and retinal thickness. Long term analyses are needed to determine if such similarity persists.
Clinical Trial: :
This PDF is available to Subscribers Only